S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
South Korean doctors hold massive anti-government rally over medical school recruitment plan
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Former Bank of Beijing chairman under investigation, part of China's crackdown on corruption
Trader Joe's chicken soup dumplings recalled for possibly containing permanent marker plastic
Critical asset just had biggest fall on record (Ad)
What to watch for as China's major political meeting of the year gets underway
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet

Crinetics Pharmaceuticals (CRNX) Stock Price, News & Analysis

$46.03
+5.09 (+12.43%)
(As of 03/1/2024 ET)
Today's Range
$41.22
$47.01
50-Day Range
$34.76
$46.03
52-Week Range
$15.23
$47.48
Volume
1.12 million shs
Average Volume
685,380 shs
Market Capitalization
$3.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.60

Crinetics Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
3.4% Upside
$47.60 Price Target
Short Interest
Healthy
6.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
0.47mentions of Crinetics Pharmaceuticals in the last 14 days
Based on 27 Articles This Week
Insider Trading
Selling Shares
$1.62 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.32) to ($3.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.23 out of 5 stars

Medical Sector

374th out of 950 stocks

Pharmaceutical Preparations Industry

175th out of 440 stocks


CRNX stock logo

About Crinetics Pharmaceuticals Stock (NASDAQ:CRNX)

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). It is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. The company was incorporated in 2008 and is headquartered in San Diego, California.

CRNX Stock Price History

CRNX Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
The Analyst Verdict: Crinetics Pharmaceuticals In The Eyes Of 6 Experts
Crinetics Pharmaceuticals Earnings Preview
CRNX Mar 2024 35.000 put
CRNX Sep 2024 55.000 call
CRNX May 2024 22.500 put
See More Headlines
Receive CRNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crinetics Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/03/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CRNX
Fax
N/A
Employees
210
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.60
High Stock Price Target
$60.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+3.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$-163,920,000.00
Net Margins
-4,223.27%
Pretax Margin
-5,216.32%

Debt

Sales & Book Value

Annual Sales
$4.01 million
Book Value
$7.75 per share

Miscellaneous

Free Float
64,724,000
Market Cap
$3.20 billion
Optionable
Optionable
Beta
0.62
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. R. Scott Struthers Ph.D. (Age 62)
    Founder, President, CEO & Director
    Comp: $870.69k
  • Dr. Stephen F. Betz Ph.D. (Age 58)
    Founder & Chief Scientific Officer
    Comp: $618.58k
  • Mr. Marc J. C. Wilson (Age 45)
    Chief Financial Officer
    Comp: $585.54k
  • Mr. James Hassard (Age 58)
    Chief Commercial Officer
    Comp: $513.34k
  • Dr. Dana Pizzuti M.D. (Age 68)
    Chief Development Officer
    Comp: $493.62k
  • Mr. Jeff E. Knight (Age 53)
    Chief Operating Officer
    Comp: $237.64k
  • Ms. Garlan Adams
    General Counsel & Corporate Secretary
  • Ms. Adriana Cabre M.B.A.
    Chief Human Resources Officer
  • Dr. Alan S. Krasner M.D. (Age 61)
    Chief Medical Officer
    Comp: $571.97k
  • Mr. Kevin Capps
    Head of Intellectual Property














CRNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Crinetics Pharmaceuticals stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CRNX shares.
View CRNX analyst ratings
or view top-rated stocks.

What is Crinetics Pharmaceuticals' stock price target for 2024?

11 analysts have issued 1-year price objectives for Crinetics Pharmaceuticals' shares. Their CRNX share price targets range from $35.00 to $60.00. On average, they predict the company's share price to reach $47.60 in the next year. This suggests a possible upside of 3.4% from the stock's current price.
View analysts price targets for CRNX
or view top-rated stocks among Wall Street analysts.

How have CRNX shares performed in 2024?

Crinetics Pharmaceuticals' stock was trading at $35.58 at the beginning of 2024. Since then, CRNX shares have increased by 29.4% and is now trading at $46.03.
View the best growth stocks for 2024 here
.

Are investors shorting Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 4,510,000 shares, a drop of 11.0% from the January 31st total of 5,070,000 shares. Based on an average trading volume of 775,700 shares, the short-interest ratio is currently 5.8 days.
View Crinetics Pharmaceuticals' Short Interest
.

When is Crinetics Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CRNX earnings forecast
.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.01. Crinetics Pharmaceuticals had a negative net margin of 4,223.27% and a negative trailing twelve-month return on equity of 52.93%. The company's quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the company earned ($0.84) EPS.

What ETF holds Crinetics Pharmaceuticals' stock ?

iShares Micro-Cap ETF holds 121,735 shares of CRNX stock, representing 0.25% of its portfolio.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

6 employees have rated Crinetics Pharmaceuticals Chief Executive Officer R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among the company's employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 68.0% of employees surveyed would recommend working at Crinetics Pharmaceuticals to a friend.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (5.24%), Point72 Asset Management L.P. (5.12%), Price T Rowe Associates Inc. MD (4.50%), Price T Rowe Associates Inc. MD (4.50%), Jennison Associates LLC (3.81%) and First Light Asset Management LLC (2.98%). Insiders that own company stock include Ajay Madan, Alan Seth Krasner, Coelho Rogerio Vivaldi, Dana Pizzuti, Jeff E Knight, Marc Wilson, Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Stephen F Betz.
View institutional ownership trends
.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CRNX) was last updated on 3/3/2024 by MarketBeat.com Staff